Core Insights - MBX Biosciences has appointed Chatan Charan, Ph.D. as Senior Vice President of Pharmaceutical Development and CMC, and Mark Hope as Senior Vice President of Regulatory and Quality, indicating a strategic move to enhance its leadership team for future growth [1][2][3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders, utilizing its proprietary PEP™ platform [4] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism in Phase 2, MBX 1416 for post-bariatric hypoglycemia in Phase 1, and an obesity portfolio with multiple candidates in various stages of development [4] Leadership Experience - Chatan Charan, Ph.D. brings over 30 years of drug development experience, previously serving at Harpoon Therapeutics and Nektar Therapeutics, where he held significant roles in product development and strategy [2][3] - Mark Hope has over 30 years of regulatory experience, having held leadership positions at Cerevel Therapeutics and Leal Therapeutics, focusing on regulatory affairs and access strategies [3]
MBX Biosciences Announces Additions to Leadership Team